SPOTLIGHT: KV buys U.S. rights to EvaMist


KV Pharmaceutical has wrapped a deal with VIVUS to buy the U.S. marketing rights to EvaMist, an estrogen transdermal spray developed to treat vasomotor symptoms associated with menopause. KV agreed to pay $10 million at closing and to make an additional payment of approximately $140 million at the time of final approval from the FDA. There are also two, one-time milestone payments tied to the net sales of the product. $10 million will be paid if the product achieves $100 million in net sales in a market year and up to $20 million will be paid if the product achieves $200 million in net sales in a market year. Release